Page 100 - 中国全科医学2022-15
P. 100

http://www.chinagp.net   E-mail:zgqkyx@chinagp.net.cn  ·1889·


           combined with MET for T2DM performed in PubMed,Cochrane Library,EMBase,Clinical Trials.gov,CNKI Database,
           VIP Database,Wanfang Databases from inception to 18 April 2021 were retrieved by computer,and the included references
           were retrieved manually. After literature screening,data extraction and quality evaluation,meta-analysis was performed using
           RevMan 5.3 software. Results A total of 9 RCTs with 6 224 patients were included. Meta-analysis results showed that the levels
           of glycosylated hemoglobin(HbA 1c ),fasting blood glucose(FPG),body weight,systolic blood pressure(SBP),diastolic
           blood pressure(DBP),and triacylglycerol(TG) in the 100 mg CANA combined with MET group and the 300 mg CANA
           combined with MET group were lower than placebo control group(P<0.05). The levels of pancreatic β-cell function index
           (HOMA-β),low-density lipoprotein cholesterol(LDL-C),and high-density lipoprotein cholesterol(HDL-C) in the
           100 mg CANA combined with MET group were higher than those in the placebo control group(P<0.05). The levels of HbA 1c  and
           SBP in the 300 mg CANA combined with MET group were lower than those in the active control group,and the level of HOMA-β
           was higher than that in the active control group(P<0.05). The FPG,body weight,DBP and TG in the 100 mg CANA combined
           with MET group and 300 mg CANA combined with MET group were lower than those in the active control group,and the levels of
           LDL-C and HDL-C were higher than those in the active control group(P<0.05). The incidence of reproductive system infection
           (female) in the 100 mg CANA combined with MET group was higher than that in the placebo control group(P<0.05). The
           incidence of reproductive system infection(female) and osmotic diuresis-related adverse events in the 300 mg CANA combined
           with MET group was higher than that in the placebo control group(P<0.05). The incidence of reproductive system infection(male),
           reproductive system infection(female),and osmotic diuresis in the 100 mg CANA combined with MET group and 300 mg
           CANA combined with MET group was higher than that in the active control group(P<0.05). Conclusion 100 mg and 300 mg
           of CANA combined with MET can effectively reduce HbA 1c  and FPG levels,body weight,blood pressure and TG levels,and
           increase LDL-C and HDL-C levels in T2DM patients. For patients with T2DM poorly controlled by MET,it may be considered
           in combination with CANA,but attention should be paid to infection of the reproductive system. Therefore,high-quality large-
           sample trials are still needed to confirm the long-term safety of different doses of CANA combined with MET.
               【Key words】 Diabetes mellitus,type 2;Canagliflozin;Metformin;Treatment outcome;Meta-analysis


               2 型糖尿病(T2DM)主要是由于胰岛素抵抗和胰岛素缺                     1 资料与方法
           乏引起。随着人们生活水平提高、人口老龄化进程加速等,                          1.1  检 索 策 略  计 算 机 检 索 PubMed、Cochrane Library、
           T2DM 患病率呈现逐年上升的趋势,T2DM 的治疗越来越受到                     EMBase、Clinical Trails.gov、中国知网、维普网、万方数据
           人们的重视   [1] 。卡格列净(CANA)是新型口服降糖药物钠 - 葡               知识 服务 平台, 检索 有关 CANA 联 合 MET 治 疗 T2DM 的
           萄糖协同转运蛋白 2(SGLT-2)抑制剂的其中一种,通过抑                      RCTs,检索时间为建库至 2021-04-18,同时手工检索纳入
           制肾小管对葡萄糖的重吸收,促进葡萄糖从尿液中排出,从                          文献的参考文献,采用主题词与自由词相结合的方式进行
           而达到降糖的目的,且降糖作用与胰岛 β 细胞的功能和胰岛                        检索,英文检索词为“Diabetes Mellitus,Type2”“Diabetes
           素的分泌均无关联      [2] 。CANA 除能够有效地控制血糖外,也               Mellitus,Noninsulin-Dependent”“NIDDM”“T2DM”“Type
           能降低体质量、血压、血脂等,对心血管有良好的保护作用,                         2 Diabetes”“Diabetes Mellitus,Maturity Onset”“MODY”
           可降低心血管死亡的风险,但也存在一些安全问题,如尿路                          “Canagliflozin”“Invokana”“TA-7284”“JNJ-
           感染、生殖器真菌感染等         [3] 。2013 年 4 月,CANA 作为美国       28431754”“Metformin”“Glucophage”“Dimethylbiguanidine”
           食品和药物监督管理局(FDA)批准的首个 SGLT-2 抑制剂,                    “Dimethylguanylguanidine”“Clinical Trial”“Randomized
                                                                                   *
           该药物已被广泛用于治疗 T2DM        [4] 。由于其独特的作用机制,            Controlled Trial”“random ”“RCT”。中文检索词为“2 型
           CANA 可单药治疗或联合治疗,如联合二甲双胍(MET)、磺                      糖尿病”“卡格列净”“二甲双胍”“随机”。
           酰脲类、二肽基肽酶 4 抑制剂(DPP-4 抑制剂)或胰岛素。                     1.2 纳入标准 (1)研究类型:国内外公开发表的关于
           MET 是受欢迎的口服降糖药物之一,因其成本低、安全记录                        CANA 联合 MET 治疗 T2DM 的 RCTs,无论是否采用盲法或者
           可靠、减轻体质量以及可能对心血管结果有好处                 [5] 。然而,      分配隐藏,语种仅限于中、英文;(2)研究对象:T2DM 患
           由于疾病的长期发展,MET 不能提供足够的血糖控制,需要                        者,年龄 >18 岁,根据美国糖尿病协会(ADA)标准诊断为
           附加其他降糖药物来维持血糖水平,因此常与其他降糖药物                          T2DM [6] ,性别、国籍不限;(3)干预时间至少为 12 周;(4)
           联合使用。在补充 MET 疗效的潜在候选药物中,许多抗高血                       每组至少 50 例;(5)干预措施:试验组给予 CANA 联合
           糖药物(AHAs)可导致低血糖或体质量增加,这可能会加重                        MET,安慰剂对照组(PBO 对照组)给予单用 MET 或者 PBO
           胰岛素抵抗。因此,本研究通过搜集国内外发表的关于 CANA                       联合 MET/ 活性对照组给予其他口服降糖药物联合 MET,试
           联合 MET 治疗 T2DM 的随机对照试验(RCTs)进行 Meta 分析,             验期间不得更改药物剂量或者更改为其他药物;(6)报告以
           以探讨 CANA 联合 MET 治疗 T2DM 的有效性以及安全性,为                 下至少1种结果:①糖化血红蛋白(HbA 1c ),②空腹血糖(FPG),
           临床治疗 T2DM 提供有效的方法。                                  ③体质量(body weight),④胰岛β细胞功能指数(HOMA-β),
   95   96   97   98   99   100   101   102   103   104   105